Intimation of Annual Report and Notice of 32nd Annual General Meeting of the Company for the F.Y.2024-25
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma has filed its 32nd Annual Report and AGM notice, with the meeting scheduled for September 20, 2025 at 11:30 AM via video conferencing. The company's FY 2024-25 revenue grew to Rs. 921.93 crores from Rs. 819.37 crores in the previous year, a 12.5% rise. Profit after tax improved to Rs. 106.5 crores (from Rs. 94.75 crores), with EBITDA at Rs. 156 crores and EPS at Rs. 20.99. No dividend has been recommended, with profits retained for expansion projects. Key developments during the year include the acquisition of Allecra Therapeutics' assets giving Orchid full global ownership of the novel antibiotic Enmetazobactam, NCLT approval for the merger of Dhanuka Laboratories into Orchid Pharma, a Rs. 600 crore 7ACA facility in Jammu, and USFDA issuing a VAI (acceptable) status inspection report.
Routine AGM procedural filing, but the attached annual report highlights strong revenue and profit growth, strategic consolidation through the Dhanuka merger, and global ownership of a novel antibiotic. For shareholders, the withheld dividend signals reinvestment in growth projects rather than near-term payouts.